|Bid||67.73 x 900|
|Ask||68.32 x 1200|
|Day's range||67.70 - 68.39|
|52-week range||56.56 - 73.34|
|Beta (5Y monthly)||0.42|
|PE ratio (TTM)||16.58|
|Earnings date||28 Oct 2021|
|Forward dividend & yield||2.84 (4.20%)|
|Ex-dividend date||14 Sept 2021|
|1y target est||76.03|
FOSTER CITY, Calif. & KENILWORTH, N.J., October 26, 2021--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the start of a Phase 2 clinical study evaluating an investigational once-weekly oral combination treatment regimen of islatravir and lenacapavir in people living with HIV who are virologically suppressed on antiretroviral therapy.
Investors will focus on the HIV franchise's performance and Veklury sales in Gilead's (GILD) third-quarter 2021 results.
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.